BridgeBio Oncology Therapeutics Inc (BBOT)
BridgeBio Oncology Therapeutics Inc is a clinical-stage biotechnology company listed on NASDAQ under the ticker BBOT. The company focuses on developing small-molecule oncology candidates in the United States, with an emphasis on pathways linked to KRAS-related cancers and related precision medicine targets. Its pipeline includes BBO-8520, a Phase I candidate being studied in patients with KRASG12C-mutant non-small cell lung cancer; BBO-11818, a Phase I pan-KRAS inhibitor; and BBO-10203, another Phase I program being evaluated across several cancer settings, including HER2-positive breast cancer, HR-positive/HER2-negative breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant non-small cell lung cancer. Founded in 2016, the company is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BBOT
|
$8.76
|
-2.6% Downside
|
Fair
|
$25.30
|
181.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-4.7x
|
1.9x
|
—
|
674.5 M
|
332.3 M
|
0.4%
|
44.5%
|
6.9
|
—
|
84.8%
|
